Evidence map›Paper›PMID 26510953›Full record

ArticleBrain : a journal of neurology2015

Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice.

Nicholas F Fitz, Victor Tapias, Andrea A Cronican, Emilie L Castranio, Muzamil Saleem, Alexis Y Carter, Martina Lefterova, Iliya Lefterov, Radosveta Koldamova

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. TemporalACS omega · 2020
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Integrated approach reveals diet, APOE genotype and sex affect immune response in APP mice.Biochimica et biophysica acta. Molecular basis of disease · 2018
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Nicholas F Fitz1 Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15219, USA.
Victor Tapias2 Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Andrea A Cronican1 Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15219, USA.
Emilie L Castranio1 Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15219, USA.
Muzamil Saleem3 Biological Sciences, Bayer School of Natural and Environmental Sciences, Duquesne University, Pittsburgh, PA 15282, USA.
Alexis Y Carter1 Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15219, USA.
Martina Lefterova4 Department of Pathology, Stanford University, Stanford, CA 94305, USA.
Iliya Lefterov1 Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15219, USA radak@pitt.edu iliyal@pitt.edu.
Radosveta Koldamova1 Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, PA 15219, USA radak@pitt.edu iliyal@pitt.edu.
University of Pittsburgh · USDuquesne University · USStanford University · USUniversity of Alabama at Birmingham · US

Funding

Epigenetic and phenotypic effects of arsenic: impacts on cognition and ADR01ES024233 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KOLDAMOVA, RADOSVETA, LEFTEROV, ILIYA · 2014 to 2018
$2.6M
Genome wide analysis of LXR binding - metabolic and epigenetic regulation in ADR01AG037919 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEFTEROV, ILIYA, SCHUG, JONATHAN · 2012 to 2016
$2.4M
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo modelsR01AG037481 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KOLDAMOVA, RADOSVETA · 2011 to 2015
$1.8M
Epigenomic impact of diet and toxicant exposure in Alzheimers disease etiologyR21ES021243 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BARCHOWSKY, AARON, LEFTEROV, ILIYA · 2012 to 2013
$468k
Peripheral & Brain Cholesterol Metabolism in Neurodegenerative Mouse ModelsK01AG044490 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FITZ, NICHOLAS FRANCIS · 2014 to 2018
$463k
NIA NIH HHS AG037481NIA NIH HHS AG037919NIA NIH HHS K01 AG044490NIA NIH HHS K01AG044490NIA NIH HHS R01 AG037481NIA NIH HHS R01 AG037919NIEHS NIH HHS ES021243NIEHS NIH HHS ES024233NIEHS NIH HHS R01 ES024233NIEHS NIH HHS R21 ES021243
6 · The paper itself

Abstract

unlabelledATP binding cassette transporter A1 (encoded by ABCA1) regulates cholesterol efflux from cells to apolipoproteins A-I and E (ApoA-I and APOE; encoded by APOA1 and APOE, respectively) and the generation of high density lipoproteins. In Abca1 knockout mice (Abca1(ko)), high density lipoproteins and ApoA-I are virtually lacking, and total APOE and APOE-containing lipoproteins in brain substantially decreased. As the ε4 allele of APOE is the major genetic risk factor for late-onset Alzheimer's disease, ABCA1 role as a modifier of APOE lipidation is of significance for this disease. Reportedly, Abca1 deficiency in mice expressing human APP accelerates amyloid deposition and behaviour deficits. We used APP/PS1dE9 mice crossed to Apoe and Apoa1 knockout mice to generate Apoe/Apoa1 double-knockout mice. We hypothesized that Apoe/Apoa1 double-knockout mice would mimic the phenotype of APP/Abca1(ko) mice in regards to amyloid plaques and cognitive deficits. Amyloid pathology, peripheral lipoprotein metabolism, cognitive deficits and dendritic morphology of Apoe/Apoa1 double-knockout mice were compared to APP/Abca1(ko), APP/PS1dE9, and single Apoa1 and Apoe knockouts. Contrary to our prediction, the results demonstrate that double deletion of Apoe and Apoa1 ameliorated the amyloid pathology, including amyloid plaques and soluble amyloid. In double knockout mice we show that (125)I-amyloid-β microinjected into the central nervous system cleared at a rate twice faster compared to Abca1 knockout mice. We tested the effect of Apoe, Apoa1 or Abca1 deficiency on spreading of exogenous amyloid-β seeds injected into the brain of young pre-depositing APP mice. The results show that lack of Abca1 augments dissemination of exogenous amyloid significantly more than the lack of Apoe. In the periphery, Apoe/Apoa1 double-knockout mice exhibited substantial atherosclerosis and very high levels of low density lipoproteins compared to APP/PS1dE9 and APP/Abca1(ko). Plasma level of amyloid-β42 measured at several time points for each mouse was significantly higher in Apoe/Apoa1 double-knockout then in APP/Abca1(ko) mice. This result demonstrates that mice with the lowest level of plasma lipoproteins, APP/Abca1(ko), have the lowest level of peripheral amyloid-β. Unexpectedly, and independent of amyloid pathology, the deletion of both apolipoproteins worsened behaviour deficits of double knockout mice and their performance was undistinguishable from those of Abca1 knockout mice. Finally we observed that the dendritic complexity in the CA1 region of hippocampus but not in CA2 is significantly impaired by Apoe/Apoa1 double deletion as well as by lack of ABCA1. IN

conclusion(i) plasma lipoproteins may affect amyloid-β clearance from the brain by the 'peripheral sink' mechanism; and (ii) deficiency of brain APOE-containing lipoproteins is of significance for dendritic complexity and cognition.

Indexed as

Gene DeletionAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsApolipoprotein A-IApolipoproteins EATP Binding Cassette Transporter 1BrainCognition DisordersFemaleHippocampusLipoproteinsMaleMiceMice, KnockoutMicroinjectionsAbca1 protein, mouseAmyloid beta-Peptidesamyloid beta-protein (1-42)Amyloid beta-Protein PrecursorApolipoprotein A-IApolipoproteins EATP Binding Cassette Transporter 1LipoproteinsPeptide FragmentsABCA1Alzheimer’s diseaseAPOA1APOEbehaviour

Identifiers

PMID26510953
PMCPMC4731410
OpenAlexW1835737391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.